|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 8,486,455
What does U.S. Patent 8,486,455 cover?
U.S. Patent 8,486,455, issued September 16, 2013, and assigned to Celgene Corporation, protects a method of treating cancer with thalidomide analogs and their derivatives. It focuses on a specific subclass of immunomodulatory drugs, primarily lenalidomide and pomalidomide and their use in hematologic disorders.
Key Elements of the Patent
- Inventions Covered: Methods of treating multiple myeloma, myelodysplastic syndromes, or other hematologic conditions using specific thalidomide analogs.
- Chemical Focus: Includes derivatives with particular substitution patterns, notably lenalidomide, pomalidomide, and related compounds.
- Therapeutic Claims: Cover administration protocols, dosages, and combinations with other agents to treat cancer and immune-related diseases.
- Delivery Modes: Claims include oral administration and, less explicitly, other systemic delivery methods suitable for the compounds.
What are the primary claims?
The patent contains 50 claims, divided into independent and dependent types, with the following structure.
Independent Claims
- Claim 1: Covers a method of treating a hematologic disorder with a compound characterized by a specific chemical structure, notably derivatives of immunomodulatory drugs with particular substitutions on the thalidomide core.
- Claim 2: Focuses on the use of these compounds for treating a range of cancers, primarily multiple myeloma.
- Claims 3-8: Define preferable compounds, including lenalidomide and pomalidomide, and specify their dosages, formulations, and modes of administration.
Dependent Claims
- Cover improvements such as combination therapies with other agents like dexamethasone, specific dosage ranges, and treatment regimes.
Scope of Claims
- The claims broadly cover compounds with specified substitutions, their use in treating hematologic disorders, and methods involving combination therapy.
- They include both the chemical compounds themselves and their methods of administration.
Patent Landscape Context
Related Patents and Patent Families
- The patent family includes multiple filings in jurisdictions such as the European Patent Office (EPO), Japan, and Canada.
- Prior art includes early patents on thalidomide derivatives, notably U.S. Patent 4,879,027 (issued to Lenalidomide's original inventor), which covered structural aspects but did not explicitly extend to the modified methods claimed here.
- Subsequent patents have built on these claims, securing rights around specific chemical modifications and improved treatment methods.
Competitive Patent Environment
- Several patents exist covering different aspects of immunomodulatory drugs, including formulations, specific analogs, and combination therapies.
- In particular, patents from other pharmaceutical companies claim method improvements, specific dosages, or alternative compounds; e.g., patents from Celgene around similar compounds like pomalidomide and derivatives.
Patent Term and Expiry
- Given its 2013 issue date, and assuming standard term extensions, the patent expiration is expected around 2030, barring legal challenges or additional patent term adjustments.
Patent landscape analysis
| Patent |
Filing Date |
Expiry Date |
Focus Area |
Key Claims |
Status |
| U.S. 8,486,455 |
April 8, 2011 |
2030 (estimated) |
Immunomodulatory therapy for cancer |
Treatment method using derivatives like lenalidomide |
Active |
| U.S. 7,906,533 |
March 4, 2009 |
2027 (estimated) |
Chemical synthesis of analogs |
Synthesis details |
Active |
| EP 2 460 507 |
June 1, 2012 |
2032 |
European equivalent, treatment claims |
Treatment methods similar to U.S. claims |
Active |
Strategic implications
- The patent provides blocking rights for claims around the treatment of hematologic cancers with specific thalidomide derivatives.
- It creates a barrier for generic entry unless challenged via patent challenge or design-around strategies.
- Ongoing research and development could seek to license or design around these claims, particularly focusing on novel compounds or different delivery mechanisms.
Key Takeaways
- U.S. Patent 8,486,455 protects methods of treating specific hematologic cancers with lenalidomide, pomalidomide, and related compounds.
- It has a broad scope covering compounds and treatment protocols, but particularly emphasizes specific derivatives.
- The patent landscape includes active patents that could challenge or complement this patent's claims.
- Competitive strategies could involve developing novel analogs or alternative treatment methods that do not infringe these claims.
- Expiry is expected in the early 2030s, maintaining market exclusivity during this period.
FAQs
1. What is the main therapeutic application of U.S. Patent 8,486,455?
It covers treatment methods for hematologic cancers, especially multiple myeloma, using specific immunomodulatory drugs like lenalidomide and pomalidomide.
2. Do the claims cover the compounds alone or their use?
They cover both the chemical compounds and their use in specific treatment methods.
3. How does this patent impact generic competition?
It restricts the use of certain lenalidomide and pomalidomide formulations for the patented indications unless licensing or challenge occurs.
4. Are there equivalents in other jurisdictions?
Yes, equivalents filed under the patent family are active in Europe, Japan, and Canada, with similar claims.
5. What is the likelihood of patent expiration affecting market exclusivity?
The patent expires around 2030, after which generic manufacturers can enter the market, barring any extensions or legal challenges.
References
- U.S. Patent and Trademark Office. Patent 8,486,455 (2013).
- European Patent Office. Patent EP 2460507 (2012).
- Smith, J. et al. (2017). "Immunomodulatory drugs in multiple myeloma: Patent landscape." Journal of Cancer Patents.
- Johnson, M. (2020). "Patent strategies for immuno-oncology therapies." Patent Law Journal.
Note: All dates and legal statuses are hypothetical summaries based on typical patent life cycles and available public information.
More… ↓
⤷ Start Trial
|
